Download Files:
Vonoprazan (Fumarate)
$50 – $170
Products Details
Product Description
– Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2].
Web ID
– HY-15295
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Molecular Formula
– C21H20FN3O6S
Citations
– Drug Dev Res. 2022 Dec 9.|Drug Metab Dispos. 2016 Oct;44(10):1543-9. |Br J Clin Pharmacol. 2019 Jul;85(7):1454-1463.
References
– [1]Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456.|[2]Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238.
CAS Number
– 881681-01-2
Molecular Weight
– 461.46
Compound Purity
– 99.88
SMILES
– O=C(O)/C=C/C(O)=O.O=S(N1C=C(CNC)C=C1C2=CC=CC=C2F)(C3=CC=CN=C3)=O
Clinical Information
– Launched
Research Area
– Metabolic Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Proton Pump
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
